At a Glance
Atlas Venture is a venture capital firm based in Cambridge, MA founded in 1980. Thirty years at the leading-edge of medical innovation and we’re just getting started. The firm focuses on Seed, Series A investments across sectors including Biotech. The firm manages $3B in assets under management. Notable portfolio companies include Fulcrum Therapeutics, Relay Therapeutics, KSQ Therapeutics, Nurix Therapeutics and Tango Therapeutics. Venture creation firm building breakthrough biotech startups in partnership with exceptional entrepreneurs and scientists.
“Venture creation firm building breakthrough biotech startups in partnership with exceptional entrepreneurs and scientists.”
Atlas Venture primarily invests at the Seed, Series A stages. This means they focus on companies that are building their initial product and finding product-market fit.
Atlas Venture is headquartered in Cambridge, MA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Atlas Venture focuses on investments in Biotech. Their portfolio reflects deep expertise and networks within these sectors.
Atlas Venture's typical investment check size ranges from $500K to $1M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Atlas Venture manages approximately $3B in assets under management (AUM) across their funds.
Running a fund like Atlas Venture? Independent guides to the software and processes emerging managers use to operate.
Best Fund Admin Software for Emerging Managers
Independent breakdown of fund administration platforms by fund size.
LP Reporting Software
Tools for capital account statements and investor updates.
Portfolio Monitoring Tools
How GPs track company performance across the portfolio.
VC CRM Software
Deal-flow and relationship management for investors.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
